Regulus Therapeutics (NASDAQ:RGLS) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.12), MarketWatch Earnings reports. Regulus Therapeutics had a negative net margin of 351.32% and a negative return on equity of 215.33%.
NASDAQ RGLS traded down $0.02 on Friday, reaching $0.62. 15,948 shares of the company’s stock traded hands, compared to its average volume of 1,350,830. The stock has a market cap of $15.04 million, a PE ratio of -0.61 and a beta of 2.04. Regulus Therapeutics has a 12 month low of $0.43 and a 12 month high of $1.74. The stock has a 50-day simple moving average of $0.77 and a 200 day simple moving average of $0.72.
Several brokerages have recently commented on RGLS. HC Wainwright reissued a “buy” rating on shares of Regulus Therapeutics in a report on Thursday, July 23rd. Needham & Company LLC initiated coverage on shares of Regulus Therapeutics in a report on Friday, May 15th. They issued a “hold” rating on the stock. Zacks Investment Research cut shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Wedbush reiterated a “hold” rating and issued a $1.00 target price on shares of Regulus Therapeutics in a research report on Friday, July 24th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $1.08.
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Further Reading: Conference Calls and Individual Investors
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.